Cited by 147Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentPeptidase Inhibition and Analysis

The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.

Current and Emerging Therapies in Metastatic Pancreatic Cancer

Manji, Gulam Abbas, Olive, Kenneth P., Saenger, Yvonne M., Oberstein, Paul·2017·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-16-2319

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Targeted therapies and immunotherapy have changed the face of multiple solid malignancies, including metastatic melanoma and lung cancer, but no such therapies exist for pancreatic ductal adenocarcinoma (PDAC) despite the knowledge of key mutations and an increasing understanding of the tumor microenvironment. Until now, most clinical studies have not been biomarker driven in this highly immunosuppressive and heterogeneous cancer. Ongoing basic and translational studies are better classifying the disease in hopes of identifying critical pathways that distinguish the unique PDAC subtypes, which will lead to personalized therapies. In this review, we discuss the current treatment options for metastatic pancreatic cancer and highlight current ongoing clinical trials, which aim to target the stroma and the immune microenvironment either alone or in combination with standard chemotherapy. Identifying biomarkers and key resistance pathways and targeting these pathways in a personalized manner in combination with chemotherapy are likely to yield a more immediate and durable clinical benefit.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-2319

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer statistics, 2016
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Of the monotherapy ICBs tested, ipilimumab resulted in one delayed response (of the 27 treated), whereas none of the 14 patients treated with BMS-936559, a programmed death-ligand 1 (PD-L1)–directed IgG4 monoclonal antibody, experienced an objective response (36, 37).”
Result
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Pancreatic Cancer
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T. B., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Petrylak, D. P., Teng, S.-L. M., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,410
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Hyaluronan: from extracellular glue to pericellular cue
Toole, B. P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1391 · Cited by 2,125
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,891
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira‐Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M. L., Balmañà, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,734
Pancreatic cancer
Li, D., Xie, K., Wolff, R. A., & Abbruzzese, J. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15841-8 · Cited by 1,731
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Mutant p53: one name, many proteinsPreprint
Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,290
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Royal, R. E., Levy, C. L., Turner, K. M., Mathur, A., Hughes, M. S., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C.-H., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,266
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00986-1 · Cited by 1,222 · cited 1×
“In 2015, combination nanoliposomal irinotecan and 5-FU was the first regimen approved by the FDA for secondline therapy in PDAC (26).”
Background
Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
Mitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D. H., Collins, L. I., Piwnica-Worms, D. R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2731 · Cited by 964
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
Louvet, C., Labianca, R., Hammel, P. R., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M. P., Aitini, E., Taı̈eb, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.023 · Cited by 948
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki–Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 857
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Kindler, H. L., Niedzwiecki, D., Hollis, D. R., Sutherland, S., Schrag, D., Hurwitz, H. I., Innocenti, F., Mulcahy, M. F., O'Reilly, E. M., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 848
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Nywening, T. M., Wang‐Gillam, A., Sanford, D. E., Belt, B. A., Panni, R. Z., Cusworth, B. M., Toriola, A. T., Nieman, R., Worley, L. A., Yano, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00078-4 · Cited by 847
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D. B., Steward, W. P., Harper, P., Dunn, J., Smith, C. T., West, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2446 · Cited by 822
Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297
Berlin, J. D., Catalano, P. J., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 728
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schönekäs, H., Rost, A., Neuhaus, H., Haag, C., Clemens, M., Heinrich, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1490 · Cited by 682
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 643
Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
Sanford, D. E., Belt, B. A., Panni, R. Z., Mayer, A., Deshpande, A. D., Carpenter, D. H., Mitchem, J. B., Plambeck-Suess, S. M., Worley, L. A., Goetz, B. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0525 · Cited by 631
Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B. L. G., Bajetta, E., Schueller, J., Saletti, P., Bauer, J. A., Figer, A., Pestalozzi, B. C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0886 · Cited by 594
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
Garrido‐Laguna, I., & Hidalgo, M. M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.53 · Cited by 576
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 568
CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma
Fukunaga, A., Miyamoto, M., Cho, Y., Murakami, S., Kawarada, Y., Oshikiri, T., Kato, K., Kurokawa, T., Suzuoki, M., Nakakubo, Y., et al. (2003) · Pancreas · doi:10.1097/00006676-200401000-00023 · Cited by 532
Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
Oettle, H., Riess, H. B., Stieler, J., Heil, G., Schwaner, I., Seraphin, J., Görner, M., Mölle, M., Greten, T. F., Lakner, V., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6995 · Cited by 492
Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
Golan, T., Kanji, Z. S., Epelbaum, R., Devaud, N., Dagan, E., Holter, S., Aderka, D., Paluch–Shimon, S., Kaufman, B., Gershoni‐Baruch, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.418 · Cited by 442
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
Poplin, E. A., Feng, Y., Berlin, J. D., Rothenberg, M. L., Höchster, H. S., Mitchell, E. P., Alberts, S. R., O'Dwyer, P. J., Haller, D. G., Catalano, P. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9007 · Cited by 437
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7401 · Cited by 398
Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer
Khorana, A. A., Ahrendt, S. A., Ryan, C., Francis, C. W., Hruban, R. H., Hu, Y. C., Hostetter, G. H., Harvey, J. L., & Taubman, M. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2351 · Cited by 394
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
Pelzer, U., Schwaner, I., Stieler, J., Adler, M., Seraphin, J., Dörken, B., Riess, H. B., & Oettle, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.011 · Cited by 369
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee, J.-M., Ledermann, J. A., & Kohn, E. C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt384 · Cited by 362
Targeting Oncogenic Mutant p53 for Cancer Therapy
Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 345
Pancreatic cancer: why is it so hard to treat?
Oberstein, P. E., & Olive, K. P. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13478680 · Cited by 334
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
Maraveyas, A., Waters, J. S., Roy, R., Fyfe, D. W., PROPPER, D. J., Lofts, F. J., Sgouros, J., Gardiner, E., Wedgwood, K. R., Ettelaie, C., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.017 · Cited by 316
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
Colucci, G., Labianca, R., Costanzo, F. D., Gebbia, V., Cartenì, G., Massidda, B., Dapretto, E., Manzione, L., Piazza, E., Sannicolò, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4433 · Cited by 303
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
Gill, S., Ko, Y., Cripps, C., Beaudoin, A., Dhesy‐Thind, S., Zulfiqar, M., Zalewski, P., Do, T., Cano, P., Lam, W. Y. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.5776 · Cited by 292
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Senzer, N. N., Nemunaitis, J. J., Nemunaitis, D., Bedell, C., Edelman, G. M., Barve, M. A., Nunan, R., Pirollo, K. F., Rait, A. S., & Chang, E. H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.32 · Cited by 250
Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer
Eriksson, E., Wenthe, J., Irenaeus, S., Loskog, A., & Ullenhag, G. J. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1037-z · Cited by 225
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Stein, S., James, E. S., Deng, Y., Cong, X., Kortmansky, J. S., Li, J., Staugaard, C., Doddamane, I., Boustani, A. M., Patel, V. V., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.45 · Cited by 209
Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma
Mahaseth, H., Brutcher, E., Kauh, J. S. W., Hawk, N. N., Kim, S., Chen, Z., Kooby, D. A., Maithel, S. K., Landry, J. C., & El‐Rayes, B. F. (2013) · Pancreas · doi:10.1097/mpa.0b013e31829e2006 · Cited by 208
Identification of germline genetic mutations in patients with pancreatic cancer
Salo‐Mullen, E. E., O'Reilly, E. M., Kelsen, D. P., Ashraf, A. M., Lowery, M. A., Yu, K. H., Reidy‐Lagunes, D. L., Epstein, A. S., Lincoln, A., Saldia, A., et al. (2015) · Cancer · doi:10.1002/cncr.29664 · Cited by 198
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas
PLATE, J. M. D., Plate, A. E., Shott, S., Bograd, S., & Harris, J. E. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0638-1 · Cited by 176
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
Yoo, C., Hwang, J. Y., Kim, J. H., Kim, T. W., Lee, J. S., Park, D. H., Lee, S. K., Seo, D. W., Lee, S. S., Kim, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605374 · Cited by 169
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
Fuchs, C. S., Azevedo, S. J., Okusaka, T., Laethem, J. V., Lipton, L. R., Riess, H. B., Szczylik, C. A., Moore, M. J., Peeters, M., Bodoky, G., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv027 · Cited by 168
Strategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M. M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 166
Pancreatic Ductal Adenocarcinoma Contains an Effector and Regulatory Immune Cell Infiltrate that Is Altered by Multimodal Neoadjuvant Treatment
Shibuya, K. C., Goel, V., Xiong, W., Sham, J. G., Pollack, S. M., Leahy, A. M., Whiting, S. H., Yeh, M. M., Yee, C., Riddell, S. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096565 · Cited by 120
Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy
Camp, E. R., Wang, C., Little, E. C., Watson, P. M., Pirollo, K. F., Rait, A. S., Cole, D. J., Chang, E. H., & Watson, D. K. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.9 · Cited by 115
Prognostic Impact of Hyaluronan and Its Regulators in Pancreatic Ductal Adenocarcinoma
Cheng, X., Sato, N., Kohi, S., & Yamaguchi, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080765 · Cited by 112
MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
Fitzgerald, J. B., Johnson, B. W., Baum, J., Adams, S., Iadevaia, S., Tang, J., Rimkunas, V. M., Xu, L., Kohli, N., Rennard, R., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0255 · Cited by 106
The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology
Pollak, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0998 · Cited by 97
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial
Scheithauer, W., Ramanathan, R. K., Moore, M. J., Macarulla, T. M., Goldstein, D., Hammel, P. R., Kunzmann, V., Liu, H., McGovern, D. M. T., Romano, A., et al. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.01.03 · Cited by 67
PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.
Le, D. T., Uram, J. N., Wang, H., Kemberling, H., Eyring, A. D., Bartlett, B. R., Goldberg, R. M., Crocenzi, T. S., Fisher, G. A., Lee, J. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.195 · Cited by 64
CXCR2: a target for pancreatic cancer treatment?
Hertzer, K. M., Donald, G. W., & Hines, O. J. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.772137 · Cited by 53
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer
Rajeshkumar, N. V., Yabuuchi, S., Pai, S. G., Tong, Z., Hou, S., Bateman, S., Pierce, D. W., Heise, C. C., Hoff, D. D. V., Maitra, A., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.215 · Cited by 51
Pancreatic cancer and FOLFIRINOX : a new era and new questions
Marsh, R., Talamonti, M., Katz, M. H. G., & Herman, J. M. (2015) · Cancer Medicine · doi:10.1002/cam4.433 · Cited by 44
Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity
Melisi, D., Ossovskaya, V., Zhu, C., Rosa, R., Ling, J., Dougherty, P. M., Sherman, B. M., Abbruzzese, J. L., & Chiao, P. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0910 · Cited by 40
Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic
Borecká, M., Zemánková, P., Vočka, M., Souček, P., Soukupová, J., Kleiblová, P., Sevcik, J., Kleibl, Z., & Janatová, M. (2016) · Cancer Genetics · doi:10.1016/j.cancergen.2016.03.003 · Cited by 33
RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.
Domchek, S. M., Hendifar, A. E., McWilliams, R. R., Geva, R., Epelbaum, R., Biankin, A. V., Vonderheide, R. H., Wolff, R. A., Alberts, S. R., Giordano, H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.4110 · Cited by 27
Interim results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer.
Hingorani, S. R., Harris, W. P., Seery, T. E., Zheng, L., Sigal, D. S., Hendifar, A. E., Braiteh, F., Zalupski, M. M., Baron, A. D., Bahary, N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.439 · Cited by 26
Efficacy and safety of FOLFIRINOX in patients with metastatic pancreatic cancer.
Metges, J. P., Ramée, J. F., Douillard, J., Boucher, É., Faroux, R., Guerin‐Meyer, V., Cumin, I., Miglianico, L., Roux, C. L., Dupuis, O., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.305 · Cited by 14
The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells
Tavor, S., Weiss, I. D., Beider, K., Wald, H., Eizenberg, O., Pereg, Y., Klapper, L. N., Nagler, A., Peled, A., & Abraham, M. (2013) · Blood · doi:10.1182/blood.v122.21.3939.3939 · Cited by 5
Thoracic Irradiation – Induced Lymphopenia in Mice
Sutherland, J., & Maruyama, Y. (2009) · Oncology · doi:10.1159/000224942 · Cited by 5
P-286 Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study
Vincent, P., Caio, R. L., Sahai, V., Simeone, D. M., Allyson, O., Philip, P., Saif, M. W., Kalyan, A., Michael, O., Jack, S. L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw199.276 · Cited by 4

Research works printed but not linked: 1

Khalil, 2016, Modern immunotherapy for the treatment of advance gastrointestinal cancers, Oncology, 30, 85

Sorted by citations

Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., Quesada, P., Sahin, I., Chandra, V., San Lucas, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.008 · Cited by 1,577
“This represents a significant unmet need, as most chemotherapeutic and immunotherapeutic agents that have proven efficacy in other malignancies have limited efficacy in PDAC (Garrido-Laguna and Hidalgo, 2015; Manji et al., 2017).”
Background
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
Orth, M., Metzger, P., Gerum, S., Mayerle, J. V., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 523
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs
Qi, R., Bai, Y., Li, K., Liu, N., Xu, Y., Dal, E., Wang, Y., Lin, R., Wang, H., Liu, Z., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100960 · Cited by 321
Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia
McDonald, P. C., Chafe, S. C., Brown, W. S., Saberi, S., Swayampakula, M., Venkateswaran, G., Nemirovsky, O., Gillespie, J. A., Karasinska, J. M., Kalloger, S. E., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.004 · Cited by 224
Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility
Dragomir, M. P., Kopetz, S., Ajani, J. A., & Călin, G. A. (2020) · Gut · doi:10.1136/gutjnl-2019-318279 · Cited by 211

See all 147

Authors: Manji, G. A., Olive, K. P., Saenger, Y. M., & Oberstein, P.
Affiliations: NewYork–Presbyterian Hospital (US)
Columbia University Irving Medical Center (US)
Corresponding author: Manji, Gulam Abbas
ORCID: Manji, Gulam Abbas
Olive, Kenneth P.
Saenger, Yvonne M.
Oberstein, Paul
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2017-04-01
Volume: 23
Issue: 7
Pages: 1670-1678
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-16-2319
OpenAlex: W2605366445
Cited by: 145
References: 77
Citations by year: 2026: 5 · 2025: 6 · 2024: 9 · 2023: 19 · 2022: 19 · 2021: 12 · 2020: 26 · 2019: 23 · 2018: 12 · 2017: 13
FWCI: 2.13
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
Keywords: metastatic pancreatic cancer, pancreatic ductal adenocarcinoma, targeted therapy, immunotherapy, tumor microenvironment, biomarkers, drug resistance, personalized treatment, combination chemotherapy, clinical trials
MeSH terms: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Humans, Immunotherapy, Neoplasm Metastasis, Neoplasms, Second Primary, Carcinoma, Pancreatic Ductal, Precision Medicine, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Current and Emerging Therapies in Metastatic Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks